ADAPT Health (AHCO) Q1 2023: Sleep Census Jumps 53% as Diabetes Channel Shift Compresses Margins
ADAPT Health’s Q1 spotlighted a sharp divergence: surging sleep equipment demand offset by diabetes business headwinds from rapid payer channel shifts. Management is betting on cost controls and value-based contracts to stabilize margins and restore growth. Execution on cost savings and new payer models will be the critical watchpoints for the rest of 2023.
Summary
- Sleep Demand Outpaces Market: Patient rental census and setups hit record highs, driving outperformance in the largest segment.
- Diabetes Channel Shift Compresses Margins: Pharmacy migration and pump mix eroded profitability, forcing rapid cost realignment.
- Strategic Contracts and Cost Actions Set Stage: Value-based care wins and $40M cost program are positioned to stabilize results in the second half.
Business Overview
ADAPT Health is a leading provider of home medical equipment and supplies, specializing in sleep therapy (CPAP), diabetes management (CGM and pumps), respiratory services, and home medical equipment (HME). The company generates revenue through equipment rentals, product sales, and recurring supply shipments, serving over 3.9 million patients across 47 states. Its business is anchored in sleep therapy, with diabetes and respiratory segments as additional growth and diversification levers.
Performance Analysis
Q1 results underscored a tale of two businesses: Sleep, the company’s largest segment, delivered standout growth, with net revenues up 18% and patient rental census surging 53% from post-recall lows. This performance was attributed to accelerated market share gains following the Philips recall and ongoing strong demand for PAP setups and resupplies.
However, the diabetes segment faced acute headwinds as payer-driven shifts moved patients from the higher-margin DME (durable medical equipment) channel to pharmacy distribution, compressing both revenue and profitability. The diabetes pump and supplies subsegment saw a $9 million YoY revenue decline, and the overall diabetes business posted negative organic growth despite an 8.3% CGM patient census increase. Adjusted EBITDA margin dropped by 150 basis points to 18%, primarily due to diabetes mix and channel pressures, even as labor and distribution costs were tightly managed.
- Sleep Segment Drives Growth: Outperformance in sleep, now the largest and fastest-growing category, provided a crucial offset to diabetes weakness.
- Diabetes Channel Migration Accelerates: Rapid payer and manufacturer shifts to pharmacy squeezed margins, with pump revenue now just over 20% of diabetes sales.
- Cost Controls and Working Capital Gains: Labor expense held steady at 25.9% of revenue, while day sales outstanding improved by five days YoY, reflecting effective revenue cycle management.
Management reaffirmed full-year guidance but signaled results will likely track toward the lower end of the range, pending the impact of new value-based contracts and full realization of cost savings in the second half.
Executive Commentary
"We are the nation's leading provider of sleep equipment-related supplies. And we had another exceptional quarter in this business, delivering 18% growth in net revenues. We believe that the extraordinary efforts we undertook to maintain our supply and setup of PAP units during the Philips recall and pandemic have resulted in increased market share and accelerated setups."
Steve Griggs, Chief Executive Officer
"The adjusted EBITDA for the quarter was $134 million, which declined 2.7% from the first quarter of 2022 and was below internal expectations... We believe we can generate annualized cost savings of approximately $40 million, with $25 million expected to be realized in calendar 2023."
Jason Clemens, Chief Financial Officer
Strategic Positioning
1. Sleep Segment as Core Growth Engine
Sleep therapy remains the anchor of ADAPT Health’s business model, delivering the highest growth and driving overall revenue stability. Record rental census and accelerated setups following the Philips recall have entrenched AHCO’s leadership, with the company leveraging its national scale to capture market share.
2. Diabetes Realignment and Channel Risk Management
The diabetes business is undergoing a structural shift as payers and manufacturers push patients to the pharmacy channel, eroding DME revenues and compressing margins. Management is actively pivoting to focus on government payers and cost reductions, aiming to stabilize the segment and restore sequential growth in the back half of the year.
3. Value-Based Care and Payer Partnerships
ADAPT Health is investing in value-based contracts with managed care organizations, moving toward exclusive, capitated arrangements that promise incremental market share and margin upside. The upcoming announcement of the company’s largest-ever contract signals a strategic push to reshape its payer mix and revenue model for more predictable, scalable growth.
4. Technology and Patient Engagement
The launch of ADAPT MyApp, a patient-facing digital platform, is a cornerstone of the ADAPT 2.0 strategy. Initial traction in the diabetes population (50,000 downloads, 7,500 orders) positions the company to deepen patient engagement, streamline logistics, and enable more integrated chronic disease management across sleep and respiratory lines.
5. Cost Structure Optimization
With $40 million in annualized cost savings targeted for 2023, ADAPT Health is reshaping its cost base through organizational redesign, footprint rationalization, and supplier renegotiation. These actions are designed to defend margins in the face of mix and reimbursement pressures without sacrificing service levels or growth capacity.
Key Considerations
This quarter marks a strategic inflection as ADAPT Health navigates both opportunity and disruption across its core business lines. Investors should weigh the following:
Key Considerations:
- Segment Divergence Intensifies: Sleep segment outperformance is now critical to offsetting diabetes volatility, amplifying the importance of maintaining share and execution in this core line.
- Diabetes Channel Exposure Remains a Drag: Pharmacy migration and pump revenue decline are structural, not cyclical, requiring ongoing adaptation and cost discipline.
- Value-Based Care Offers Upside but Carries Ramp Risk: New payer contracts could drive incremental growth, but successful integration and execution are not guaranteed in year one.
- Cost Actions Must Translate to Margin Stability: The $40 million cost program is essential to defend EBITDA and free cash flow as mix shifts continue.
- Leadership Transition Adds Uncertainty: CEO succession is underway, and interim leadership may face challenges in sustaining momentum and strategic continuity.
Risks
Diabetes revenue mix shift remains the most material risk, with further payer channel changes or pricing pressure potentially eroding profitability. The success of cost savings initiatives and the pace of value-based contract ramp are not assured, especially amid ongoing leadership transition. Execution risk is heightened as the company juggles structural realignment and large-scale payer partnerships.
Forward Outlook
For Q2 2023, ADAPT Health guided to:
- Mid-single digit net revenue growth over Q2 2022
- Adjusted EBITDA margin just under 20%, with improvement expected from cost actions
For full-year 2023, management maintained guidance but expects results toward the lower end of the range:
- Full-year free cash flow between $96 and $128 million
Management highlighted several factors that will shape the rest of the year:
- Cost savings program will drive sequential margin improvement
- Value-based care contracts, not yet included in guidance, could provide upside in the second half
Takeaways
Investors face a complex setup: robust sleep demand and operational discipline are offset by diabetes channel disruption and margin compression. The company’s ability to execute on cost savings and ramp new payer contracts will determine whether it can reaccelerate earnings growth and defend its market position.
- Margin Defense Hinges on Cost Execution: Realizing targeted savings is critical to offsetting diabetes headwinds and stabilizing EBITDA.
- Value-Based Care Is a Pivotal Experiment: The scale and profitability of new contracts will be a key determinant of long-term growth and margin profile.
- Sleep Remains the Anchor: Sustained outperformance in sleep therapy is essential as other segments undergo structural change.
Conclusion
ADAPT Health’s Q1 2023 revealed strong operational execution in sleep offset by diabetes disruption, with management banking on cost controls and new payer models to restore margin and growth. Second-half results will be a referendum on the company’s ability to adapt to payer-driven channel shifts and deliver on its cost and value-based care ambitions.
Industry Read-Through
ADAPT Health’s experience is a bellwether for the broader home health and medical device distribution sector. Rapid payer channel migration in diabetes—especially toward pharmacy—signals a structural shift that will pressure DME-focused providers across the industry. Winners will be those who can pivot to value-based care, invest in patient engagement technology, and aggressively manage costs. Sleep therapy remains a growth engine for the sector, but margin defense and payer mix management are now front and center for all players exposed to chronic disease management and home medical equipment distribution.